Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level

Josh Sullivan

In January, Artiva Biotherapeutics CEO Fred Aslan said his company is looking to create CAR-NK therapies with best-in-class efficacy made in a wholly owned manufacturing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level

Josh Sullivan

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level